P476: AN ORAL COMBINATION THERAPY OF OR-2100 AND VENETOCLAX IN ACUTE MYELOID LEUKEMIA

P476: AN ORAL COMBINATION THERAPY OF OR-2100 AND VENETOCLAX IN ACUTE MYELOID LEUKEMIA

Bibliographic Details
Main Authors:	Kazuharu Kamachi, Hiroshi Ureshino, Kazunori Kawasoe, Keisuke Kidoguchi, Yuta Yamamoto, Yuki Fukuda-Kurahashi, Yuki Kurahashi, Tatsuro Watanabe, Shinya Kimura
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000968812.73633.b7

Similar Items

A Combination of Alectinib and DNA-Demethylating Agents Synergistically Inhibits Anaplastic-Lymphoma-Kinase-Positive Anaplastic Large-Cell Lymphoma Cell Proliferation
by: Kazunori Kawasoe, et al.
Published: (2023-10-01)

P413: THE POTENTIAL USE OF AN ORAL HYPOMETHYLATING AGENT, OR-2100, AS A COMBINATION THERAPY FOR MYELOID MALIGNANCIES
by: K. Kamachi, et al.
Published: (2022-06-01)

P1233: TUMOR PREVENTION USING DNA DEMETHYLATING AGENTS ON VIRUS-DERIVED CARCINOGENESIS IN MICE.
by: Yuta Yamamoto, et al.
Published: (2023-08-01)

P1236: REGULATION OF DNA AND HISTONE METHYLATION THROUGH METHIONINE METABOLISM IN ATL LEUKEMOGENESIS
by: Tatsuro Watanabe, et al.
Published: (2023-08-01)

P1301: BIOLOGICAL SIGNIFICANCE OF UCK2 IN HTLV-1-INFECTED CELLS IN ATL LEUKEMOGENESIS AND ACQUIRED RESISTANCE TO AZACITIDINE
by: T. Watanabe, et al.
Published: (2022-06-01)

Higher neutrophil counts are associated with successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia
by: Hiroshi Ureshino, et al.
Published: (2022-12-01)

Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia
by: Keisuke Kidoguchi, et al.
Published: (2021-02-01)

Venetoclax Resistance in Acute Myeloid Leukemia
by: Sylvain Garciaz, et al.
Published: (2024-03-01)

Venetoclax in adult acute myeloid leukemia
by: Mengci Hu, et al.
Published: (2023-12-01)

Deep sequencing of the T cell receptor visualizes reconstitution of T cell immunity in mogamulizumab-treated adult T cell leukemia
by: Takero Shindo, et al.
Published: (2018-03-01)

Venetoclax-containing regimens in acute myeloid leukemia
by: Ibrahim Aldoss, et al.
Published: (2021-02-01)

PB1862: VENETOCLAX AND AZACITIDINE THERAPY IN ACUTE MYELOID LEUKEMIA PATIENTS WITH SEVERE RENAL IMPAIRMENT
by: Ryosuke Naka, et al.
Published: (2023-08-01)

Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies
by: Mila S. Griffioen, et al.
Published: (2022-07-01)

Biomarkers of Response to Venetoclax Therapy in Acute Myeloid Leukemia
by: Carlos Rodríguez-Medina, et al.
Published: (2024-01-01)

Venetoclax efficacy on acute myeloid leukemia is enhanced by the combination with butyrate
by: Renshi Kawakatsu, et al.
Published: (2024-02-01)

Clinical Study of Venetoclax with Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia
by: CHEN Xiaofeng, WANG Meng, LI Zhongyu, LI Jiajia
Published: (2022-03-01)

Research progress of anti-apoptotic inhibitor venetoclax in treatment of myeloid leukemia
by: XIANG Caixia, HUANG Bintao, HAO Jian
Published: (2023-05-01)

Building on Foundations: Venetoclax-Based Combinations in the Treatment of Acute Myeloid Leukemia
by: Emmanuella Oyogoa, et al.
Published: (2023-07-01)

Pharmacokinetics of Venetoclax Co-Administered with Posaconazole in Patients with Acute Myeloid Leukemia
by: Simona De Gregori, et al.
Published: (2023-06-01)

Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?
by: Serena Brancati, et al.
Published: (2021-12-01)

Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia
by: Ian M. Bouligny, et al.
Published: (2023-05-01)

Hymeglusin Enhances the Pro-Apoptotic Effects of Venetoclax in Acute Myeloid Leukemia
by: Cheng Zhou, et al.
Published: (2022-06-01)

Venetoclax Combination Treatment of Acute Myeloid Leukemia in Adolescents and Young Adult Patients
by: Elena Chatzikalil, et al.
Published: (2024-04-01)

PB1840: MONOCENTRIC EXPERIENCE OF VENETOCLAX-BASED REGIMENS FOR ACUTE MYELOID LEUKEMIA
by: M. Sciumè, et al.
Published: (2022-06-01)

Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2
by: Xi Xu, et al.
Published: (2023-10-01)

Venetoclax plus cyclophosphamide and cytarabine as induction regimen for adult acute myeloid leukemia
by: Baohang Zhang, et al.
Published: (2023-05-01)

Real-life monocentric experience of venetoclax-based regimens for acute myeloid leukemia
by: Mariarita Sciumè, et al.
Published: (2023-03-01)

BCL-2 inhibitor venetoclax-innovating the therapeutic pattern of acute myeloid leukemia
by: WANG Xiaoling, et al.
Published: (2023-08-01)

Repurposing ribosome-targeting antibiotics to overcome resistance to venetoclax in acute myeloid leukemia
by: David Sharon, et al.
Published: (2020-03-01)

An integrative systems biology approach to overcome venetoclax resistance in acute myeloid leukemia.
by: Michelle Przedborski, et al.
Published: (2022-09-01)

Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions
by: Bachar Samra, et al.
Published: (2020-11-01)

Venetoclax-based combinations for acute myeloid leukemia: optimizing their use in Latin-America
by: Andrés Gómez-De León, et al.
Published: (2022-12-01)

Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia
by: Keith W. Pratz, et al.
Published: (2022-04-01)

A novel polyethylene glycol (PEG)‐drug conjugate of Venetoclax, a Bcl‐2 inhibitor, for treatment of acute myeloid leukemia (AML)
by: Hidenori Ando, et al.
Published: (2022-03-01)

Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia
by: Jingying Cui, et al.
Published: (2024-12-01)

P524: PHARMACODYNAMICALLY DEFINED METRONOMIC DOSING OF DECITABINE AND VENETOCLAX IN ACUTE MYELOID LEUKEMIA
by: Kateryna Fedorov, et al.
Published: (2023-08-01)

Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients
by: Sylvain Garciaz, et al.
Published: (2022-04-01)

Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience
by: Jorge Labrador, et al.
Published: (2022-03-01)

The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions
by: Matteo Piccini, et al.
Published: (2023-05-01)

Targeting Chronic Myeloid Leukemia Stem/Progenitor Cells Using Venetoclax-Loaded Immunoliposome
by: Mohammad Houshmand, et al.
Published: (2021-03-01)